Pharmacogenomics. 2012;13(13):1523-1535. 5-year survival for stage III and IV (%): carriers, 38.1; noncarriers, 24.5 Median survival: p = 0.002 5-year survival for stage III and IV: p < 0.001 [46 ...

Approximately one in 400 people, and one in 100 diagnosed with breast cancer, have a BRCA2 mutation, Couch said. People who have a BRCA2 loss-of-function pathogenic mutation have a 69% lifetime ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

Figure 1. The frequency and distribution of cancer susceptibility genes (CSGs) with more than one pathogenic/likely pathogenic germline mutation detected in patients with esophageal squamous cell ...

Additional research can now focus on reliable estimates of the mutation frequency, spectrum, penetrance and range of malignancies associated with germline CDH1 mutations. Further work to identify ...

In contrast to non-cancer genetic diseases, where significant knowledge is accumulated with regard to pathogenic role of aminoacid substitutions, the spectrum of tumor-predisposing alleles is almost ...

Olaparib is available on the NHS. It is a possible treatment for HER2-negative, locally advanced or metastatic breast cancer with inherited (germline) BRCA1 or BRCA2 mutations in adults who have had: ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

Followed categories will be added to My News. She has one of the most commonly inherited gene mutations – BRCA2 – which increases the risk of breast, ovarian and prostate cancers. Mia tested ...

and BRCA2. Smith said future research will look at whether an inherited or acquired mutation may alter clinical outcome, motivating tailored precision care. Other Vanderbilt authors include ...